Regeneration Biomedical

Executive Summary

Regeneration Biomedical (RBI) is a clinical-stage biotechnology company pioneering a novel autologous stem cell therapy for neurodegenerative diseases, including Alzheimer's disease, ALS, and Parkinson's disease. Founded in 2015 and headquartered in Provo, Utah, the company's proprietary approach involves harvesting a patient's own adipose-derived stem cells, activating them ex vivo via Wnt signaling, and then directly injecting them into the brain to bypass the blood-brain barrier. This targeted delivery method aims to address the underlying pathology of these devastating conditions by promoting neuroregeneration and reducing inflammation. RBI is currently advancing its lead candidate through Phase 1 clinical trials, focusing initially on Alzheimer's disease. The company's unique strategy differentiates it from other stem cell therapies that rely on systemic administration or allogeneic sources. While still early-stage, RBI's approach holds promise for a disease-modifying treatment in areas of high unmet medical need. The company's private status limits public financial disclosures, but its focus on a validated mechanism (Wnt signaling) and an autologous, personalized medicine model positions it well within the competitive landscape of neurodegenerative disease therapeutics. Key upcoming milestones include initial clinical data readouts and potential expansion into additional indications such as ALS and Parkinson's.

Upcoming Catalysts (preview)

• Q4 2026Interim Phase 1 Safety and Efficacy Data for Alzheimer's Disease40% success
• Q2 2026FDA Clearance to Initiate Phase 1 Trial for ALS60% success
• Q3 2026Strategic Partnership or Series B Financing Announcement50% success